Skip to content
Disclosery

Octagon Capital Advisors LP

Follow

13F filer, CIK 1839435, NEW YORK, NY

Octagon Capital Advisors LP reported $607,700,826 across 33 holdings for the quarter ended 2024-12-31, in a 13F-HR filed 2025-02-14. Its ten largest share positions make up 62.56% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001839435-25-000002

Period
2024-12-31
Reported value
$608M
Holdings
33
Top 10 weight
62.56%
New
8
Sold out
17

Largest buys vs the previous quarter

SecurityShares changeApprox. value
SRRKnew+488,000$21.1M
MERUS N Vnew+308,000$13M
ERASnew+5,136,795$12.9M
SNDXnew+904,000$12M
KALVnew+1,370,000$11.6M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
VERONA PHARMA PLCreduced-1,263,936-$58.7M
GPCRexited-1,198,000-$52.6M
ALLOVIR INCexited-11,202,000-$9.06M
EYPTexited-1,093,503-$8.74M
NUVBreduced-2,968,606-$7.9M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2024

Share positions as resolved from 13F-HR 0001839435-25-000002, largest first. % of portfolio is the value over $587,894,826, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
APLSAPELLIS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,006,980 shares; 2024Q4: 3,006,980 shares 3,006,980$96M16.32%0Timeline
AVBPARRIVENT BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,976,387 shares; 2024Q4: 2,059,387 shares 2,059,387$54.9M9.33%+83,000Timeline
DNTHDIANTHUS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,746,667 shares; 2024Q4: 2,110,167 shares 2,110,167$46M7.82%+363,500Timeline
CNTACENTESSA PHARMACEUTICALS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,012,052 shares; 2024Q4: 1,993,052 shares 1,993,052$33.4M5.68%-19,000Timeline
VERONA PHARMA PLCVERONA PHARMA PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,835,200 shares; 2024Q4: 571,264 shares 571,264$26.5M4.51%-1,263,936
NUVBNUVATION BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 12,171,513 shares; 2024Q4: 9,202,907 shares 9,202,907$24.5M4.16%-2,968,606Timeline
INSMINSMED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 436,820 shares; 2024Q4: 332,000 shares 332,000$22.9M3.9%-104,820Timeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,305,000 shares; 2024Q4: 2,763,000 shares 2,763,000$21.6M3.67%+1,458,000Timeline
SRRKSCHOLAR ROCK HLDG CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 488,000 shares 488,000$21.1M3.59%newTimeline
MIND MEDICINE MINDMED INCMIND MEDICINE MINDMED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,018,000 shares; 2024Q4: 3,018,000 shares 3,018,000$21M3.57%0
OCULOCULAR THERAPEUTIX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,425,000 shares; 2024Q4: 2,425,000 shares 2,425,000$20.7M3.52%0Timeline
TSHATAYSHA GENE THERAPIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,572,222 shares; 2024Q4: 10,450,000 shares 10,450,000$18.1M3.08%+5,877,778Timeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 870,000 shares; 2024Q4: 870,000 shares 870,000$16.7M2.84%0Timeline
GOSSGOSSAMER BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 9,187,883 shares; 2024Q4: 18,350,000 shares 18,350,000$16.6M2.82%+9,162,117Timeline
DYNDYNE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 262,726 shares; 2024Q4: 668,000 shares 668,000$15.7M2.68%+405,274Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 620,470 shares; 2024Q4: 778,000 shares 778,000$14.9M2.54%+157,530Timeline
CRBPCORBUS PHARMACEUTICALS HLDGSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,115,000 shares; 2024Q4: 1,115,000 shares 1,115,000$13.2M2.24%0Timeline
MERUS N VMERUS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 308,000 shares 308,000$13M2.2%new
ERASERASCA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 5,136,795 shares 5,136,795$12.9M2.19%newTimeline
BBIOBRIDGEBIO PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 552,000 shares; 2024Q4: 441,600 shares 441,600$12.1M2.06%-110,400Timeline
SNDXSYNDAX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 904,000 shares 904,000$12M2.03%newTimeline
KALVKALVISTA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 1,370,000 shares 1,370,000$11.6M1.97%newTimeline
UNICYCIVE THERAPEUTICS INCUNICYCIVE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 8,559,000 shares; 2024Q4: 10,000,000 shares 10,000,000$7.94M1.35%+1,441,000
REGULUS THERAPEUTICS INCREGULUS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,263,701 shares; 2024Q4: 4,848,802 shares 4,848,802$7.66M1.3%+585,101
CATXPERSPECTIVE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,422,224 shares; 2024Q4: 2,304,752 shares 2,304,752$7.35M1.25%+882,528Timeline
NGNENEUROGENE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 15,000 shares; 2024Q4: 303,000 shares 303,000$6.93M1.18%+288,000Timeline
ALLOVIR INCALLOVIR INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 11,215,000 shares 11,215,000$4.71M0.8%new
ATYRATYR PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 900,000 shares 900,000$3.26M0.55%newTimeline
HELIX ACQUISITION CORP IIHELIX ACQUISITION CORP IIQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 250,000 shares; 2024Q4: 250,000 shares 250,000$2.62M0.45%0
Mersana Therapeutics IncMersana Therapeutics IncQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 992,000 shares; 2024Q4: 992,000 shares 992,000$1.42M0.24%0
NUVATION BIO INCNUVATION BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 312,336 shares; 2024Q4: 312,336 shares 312,336$831K0.14%0

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
INSMINSMED INC Stockcall250,000$17.3M0
CNTACENTESSA PHARMACEUTICALS PLC SPONSORED ADSput152,000$2.55Mnew

Sold out in Q4 2024

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
GPCRSTRUCTURE THERAPEUTICS INC1,198,000$52.6Mshares
ALLOVIR INCALLOVIR INC11,202,000$9.06Mshares
EYPTEYEPOINT INC1,093,503$8.74Mshares
PRAXPRAXIS PRECISION MEDICINES I130,000$7.48Mshares
MLYSMINERALYS THERAPEUTICS INC600,000$7.27Mshares
VTYXVENTYX BIOSCIENCES INC2,391,114$5.21Mshares
TNYATENAYA THERAPEUTICS INC2,576,200$4.97Mshares
HELPCYBIN INC489,596$4.35Mshares
RENEO PHARMACEUTICALS INCRENEO PHARMACEUTICALS INC2,250,000$3.83Mshares
PEPGPEPGEN INC376,117$3.22Mshares
BDTXBLACK DIAMOND THERAPEUTICS I594,000$2.58Mshares
ANNXANNEXON INC400,000$2.37Mshares
IPSCCENTURY THERAPEUTICS INC666,825$1.14Mshares
AEROVATE THERAPEUTICS INCAEROVATE THERAPEUTICS INC465,440$973Kshares
AUTLAUTOLUS THERAPEUTICS LTD176,000$639Kshares
RAPT THERAPEUTICS INCRAPT THERAPEUTICS INC292,000$587Kshares
NKTXNKARTA INC120,000$542Kshares

How Q4 2024 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001839435-25-000002 base2025-02-14acceptance time not in the bulk data set